CBIO Q1 2021 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$337M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-88.3% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$14M-1353.0% margin

Net Income

-$14M-1352.4% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+547.8%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$138M

Total Liabilities

$13M

Stockholders' Equity

$125M

Cash & Equivalents

$132M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$9M	-88.3%
Gross Profit	$1M	$9M	-88.3%
Operating Income	-$14M	-$8M	-76.1%
Net Income	-$14M	-$8M	-86.3%